Canlyniadau Chwilio - Scott, Rob

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism gan Chan, Dick C., Watts, Gerald F., Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Barrett, P. Hugh R.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab gan Desai, Nihar R., Giugliano, Robert P., Wasserman, Scott M., Gibbs, John P., Liu, Thomas, Scott, Rob, Sabatine, Marc S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hyperc... gan Cho, Leslie, Rocco, Michael, Colquhoun, David, Sullivan, David, Rosenson, Robert S., Dent, Ricardo, Xue, Allen, Scott, Rob, Wasserman, Scott M, Stroes, Erik

Cael y testun llawn Cael y testun llawn Cael y testun llawn

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Par... gan Kohli, Payal, Ganz, Peter, Ma, Yifei, Scherzer, Rebecca, Hur, Sophia, Weigel, Bernard, Grunfeld, Carl, Deeks, Steven, Wasserman, Scott, Scott, Rob, Hsue, Priscilla Y.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hy... gan Robinson, Jennifer G., Rogers, William J., Nedergaard, Bettina S., Fialkow, Jonathan, Neutel, Joel M., Ramstad, David, Somaratne, Ransi, Legg, Jason C., Nelson, Patric, Scott, Rob, Wasserman, Scott M., Weiss, Robert

Cael y testun llawn Cael y testun llawn Cael y testun llawn

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role gan Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subj... gan Nissen, Steven E., Dent‐Acosta, Ricardo E., Rosenson, Robert S., Stroes, Erik, Sattar, Naveed, Preiss, David, Mancini, G.B. John, Ballantyne, Christie M., Catapano, Alberico, Gouni‐Berthold, Ioanna, Stein, Evan A., Xue, Allen, Wasserman, Scott M., Scott, Rob, Thompson, Paul D.

Cael y testun llawn Cael y testun llawn Cael y testun llawn